바이오인프라

199730KOSDAQ

56.5 / 100

Reference Date: 2026-10-23

Financial Score19.0 / 40

News Sentiment12.5 / 25

Momentum15.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 139.2% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

BioInfral is a CRO established in 2007, specializing in bioequivalence testing for generic drugs, Phase I clinical trials for improved drugs, approval clinical trials, immunoassays, and pharmaceutical quality inspections. The company operates multiple business units, including PK, Clinical, Immunoassay, and Testing, offering diverse services such as drug interaction studies, clinical trial management, biomarker analysis, and stability testing.

Number of Employees

141people

Average Salary

47.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

0.60Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE

-41.45Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

4.88Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼11.9% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼257.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -15.6% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (30%)

Current 2,040Won52-week high 5,32052-week low 618

1-month return6.0Point

1m +139.16% (strong rise)

Volume trend6.0Point

Volume surge

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral기타경영사항(자율공시) (소규모합병 승인 이사회 결의(주주총회 갈음) 결과 보고)2026-10-14
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-12
Neutral기타시장안내 (시가총액 미달에 따른 상장폐지 우려 관련 안내)2026-09-30